Stage 3/4 thyroid cancer patients also had more circulating myeloid-derived suppressor cells (MDSCs; Lin-CD33+HLADR-) as subset of mononuclear cells (2.63% vs. 1.54%; p=0.02) compared with stage1/2 (Figure 2D). This evidence concerns the gene CD33 and thyroid cancer.